21 февр. 2024 г. · January 16, 2024 Approval Letter - CASGEVY (STN 125785) · January 16, 2024 Summary Basis for Regulatory Action - CASGEVY · December 8, 2023 ...

16 янв. 2024 г. · Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia.

8 дек. 2023 г. · The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

8 дек. 2023 г. · “CASGEVY's approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S.

Casgevy received a conditional marketing authorisation valid throughout the EU on 9 February 2024. Casgevy : EPAR - ...

16 янв. 2024 г. · On Tuesday, January 16, 2024, the FDA gave the green light to Vertex Pharmaceuticals and CRISPR Therapeutics' groundbreaking Casgevy™ ...

16 янв. 2024 г. · Vertex and CRISPR Therapeutics expected an FDA decision for Casgevy in TDT by March 30, 2024. “On the heels of the historic FDA approval of ...

16 янв. 2024 г. · The endorsement arrived more than two months early as an FDA decision was due on March 30. “On the heels of the historic FDA approval of ...

16 янв. 2024 г. · “We are pleased with the approval of CASGEVY in TDT well ahead of the PDUFA date,” said Samarth Kulkarni , Ph.D., Chairman and Chief ...